Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery

Perfusion

Volumn 12, Issue 6, 1997, Pages 385-391

  Belboul, Ali ^a   Al Khaja, Najib ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4;

ADULT; AGED; ARTERY BYPASS; ARTICLE; BIOCOMPATIBILITY; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CORONARY ARTERY; FEMALE; HEART SURGERY; HEPARINIZATION; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MORBIDITY; PRIORITY JOURNAL; SURFACE PROPERTY; SURGICAL MORTALITY;

EID: 0030859667     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765919701200607     Document Type: Article

References (49)

1. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. New Engl J Med 1981; 304: 497-503.
2. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845-57.
3. Westaby S. Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Med 1987; 13: 89-95.
4. Kirklin JK. The postperfusion syndrome: inflammation and the damaging effects of cardiopulmonary bypass. In: Tinker JH, ed. Cardiopulmonary bypass: current concepts and controversies. Philadelphia, PA: WB Saunders, 1989: 131.
5. Lew PD, Forster A, Perrin LH et al. Complement activation in the adult respiratory distress syndrome following cardiopulmonary bypass. Bull Eur Physiopathol Respir 1985; 21: 231-35.
6. Van Oeveren W, Wildevuur CRH, Kazatchkine MD. Biocompatibility of extracorporeal circuits in heart surgery. Transfusion Sci 1990; 11: 5-33.
7. Kirklin JK. Prospects for understanding and eliminating the deleterious effects of cardiopulmonary bypass [Editorial]. Ann Thorac Surg 1991; 51: 529-31.
8. Royston D. Blood cell activation. Semin Thorac Cardiovasc Surg 1990; 2: 341-57.
9. Downing SW, Edmunds Jr LH. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 1236-43.
10. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 552-59.
11. Utley J. Historical perspectives and basic pathophysiology of cardiopulmonary bypass. Semin Thorac Cardiovasc Surg 1990; 2: 292-99.
12. Pasche B, Kodama K, Larm O, Olsson P, Swedenborg J. Thrombin inactivation on surfaces with covalently bonded heparin. Thromb Res 1986; 44: 739-48.
13. Kodama K, Pasche B, Olsson P et al. Anthithrombin III binding to surface immobilized heparin and its relation to FXa inhibitors. Thromb Haemost 1987; 58: 1064-67.
14. Von Segesser LK, Weiss BM, Turina MI. Perfusion with heparin coated equipment: potential for clinical use. Semin Thorac Cardiovasc Surg 1990; 2: 373-80.
15. Nilsson L, Storm KE, Thelin S et al. Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. Artif Organs 1990; 14: 46-48.
16. Arnander C, Olsson O, Larm O. Influence of blood flow and the effect of protamine on the thromboresistant properties of a covalently bonded heparin surface. J Biomed Mater Res 1988; 22: 859-68.
17. Videm V, Svennevig JL, Fosse E, Semb G, Osterud A, Mollnes TE. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992; 103: 806-13.
18. Mollnes TE, Videm V, Gotze O, Harboe M, Oppermann M. Formation of C5a during cardiopulmonary bypass: inhibition by precoating with heparin. Ann Thorac Surg 1991; 52: 92-7.
19. Von Segesser LK, Weiss BM, Garcia E, Turina ML. Clinical application of heparin-coated perfusion equipment with special emphasis on patients refusing homologous transfusion. Perfusion 1991; 6: 227-33.
20. Gu YJ, van Oeveren W, van der Kamp KWHJ, Akkerman C, Boonstra PW, Wildervuur CRH. Heparin-coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion 1991; 6: 221-25.
21. Pradhan MJ, Fleming JS, Nkere UV, Arnold J, Wildevuur CRH, Taylor KM. Clinical experience with heparin-coated cardiopulmonary bypass circuits. Perfusion 1991; 6: 235-42
22. Gu YJ, van Oeveren W, Akkerman C, Boonstra PW, Huyzen RJ, Wildevuur CRH. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 917-22.
23. Belboul A, Al-Khaja N, Gudmundsson M et al. The influence of heparin-coated and uncoated extracorporeal circulation on blood rheology during cardiac surgery. J Extra-Corpor Technol 1993; 25: 40-46.
24. Nilsson UR, Nilsson B. Simplified assays of hemolytic activity of the classical and alternative complement pathways. J Immunol Meth 1984; 72: 49-59.
25. Bourke BE, Moss IK, Maini RN. Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis. J Immunol Meth 1982; 48: 97-108.
26. Pekna M, Borowiec J, Fagerhol M, Venge P, Thelin S. Biocompatibility of heparin-coated circuits used during cardiopulmonary bypass. Scand J Thor Cardiovasc Surg 1994; 28: 5-11.
27. Cavarocchi NC, Schaff HV, Orszulak TA, Homburger HA, Schnell Jr WA, Pluth JR. Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass. Surgery 1985; 98: 525-30.
28. Pekna M, Hagman L, Halden E, Nilsson U, Nilsson B, Thelin S. Complement activation during cardiopulmonary bypass: effects of immobilised heparin. Ann Thorac Surg 1994; 58: 421-24.
29. Pekna M, Larsson R, Formgren B, Nilsson U, Nilsson B. Complement activation by polymethyl methacrylate minimized by end point heparin attachment. Biomaterials 1993; 14: 189-92.
30. Nilsson U, Larm O, Nilsson B, Storm K-E, Elwing H, Nilsson-Ekdahl K. Modification of the complement binding properties of polystyrene: effects of end-point heparin attachment. Scand J Immunol 1993; 37: 349-54.
31. Nilsson-Ekdahl K, Nilsson B, Pekna M, Nilsson U. Generation of C3 at the interface between blood and gas. Scand J Immunol 1992; 35: 85-91.
32. Pekna M, Nilsson L, Nilsson-Ekdahl K, Nilsson U, Nilsson B. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin Exp Immunol 1993; 91: 404-409.
33. Ley K, Arfors K-E. Changes in macromolecular permeability by intravascular generation for oxygen-derived free radicals. Microvasc Res 1982; 24: 25-29.
34. Martin WJ, Gadek JE, Hunninghake GW, Crystal RG. Oxidant injury of lung parenchymal cells. J Clin Invest 1981; 68: 1277-82.
35. Lindblad B, Wakefield TW, Whitehouse WM, Stanley JC. The effect of protamine sulfate on platelet function. Scand J Thorac Cardiovasc Surg 1988; 22: 55-59.
36. Wakefield TW, Till GO, Lindblad B, Saenz N, Stanley JC. Complement depletion and persistent hemodynamic-hematologic responses in protamine-heparin reactions. J Surg Res 1988; 45: 320-26.
37. Morel DR, Zapol WM, Thomas SJ et al. C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. Anesthesiology 1987; 66: 597-604.
38. Cosgrove DM, Thurer RL, Lytle BW, Gill CG, Peter M, Loop FD. Blood conservation during myocardial revascularization. Ann Thorac Surg 1979; 28: 184-89.
39. Johnson RG, Rosenkrantz KR, Preston RA, Hopkins C, Daggett WM. The efficacy of postoperative autotransfusion in patients undergoing cardiac operations. Ann Thorac Surg 1983; 36: 173-79.
40. Schaff HV, Hauer J, Gardner TJ et al. Routine use of autotransfusion following cardiac surgery: experience in 700 patients. Ann Thorac Surg 1979; 27: 493-99.
41. Lepore V, Radegran K. Autotransfusion of mediastinal blood in cardiac surgery. Scand J Thorac Cardiovasc Surg 1989; 23: 47-49.
42. Eng J, Kay PH, Murday AJ et al. Postoperative autologous transfusion in cardiac surgery: a prospective, randomized study. Eur J Cardiothorac Surg 1990; 4: 595-600.
43. Thurer RL, Lytle BW, Cosgrove DM, Loop FD. Autotransfusion following cardiac operations: a randomized, prospective study. Ann Thorac Surg 1979; 27: 500-507.
44. Adan A, Brutel de la Riviere A, Haas F, van Zalk A, de Nooij E. Autotransfusion of drained mediastinal blood after cardiac surgery: a reappraisal. Thorac Cardiovasc Surg 1988; 36: 10-14.
45. Page R, Russell GN, Fox MA, Fabri BM, Lewis I, Williets T. Hard-shell cardiotomy reservoir for reinfusion of shed mediastinal blood. Ann Thorac Surg 1989; 48: 514-17.
46. Hartz RS, Smith JA, Green D. Autotransfusion after cardiac operation. Assessment of hemostatic factors. J Thorac Cardiovasc Surg 1988; 96: 178-82.
47. Griffith LD, Billman GF, Daily PO, Lane TA. Apparent coagulopathy caused by infusion of shed madiastinal blood and its prevention by washing of the infusate. Ann Thorac Surg 1989; 47: 400-406.
48. Marder VJ, Machett MO, Sherry S. Detection of serum fibrinogen and fibrin degradation products. Comparison of six techniques using purified products and application in clinical studies. Am J Med 1971; 51: 71-76.
49. Schonberger JPAM, van Oeveren W, Bredee JJ, Everts PAM, de Haan J, Wildevuur CRH. Systemic blood activation during and after autotransfusion. Ann Thorac Surg 1994; 57: 1256-62.